Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model

Nutrition and Cancer

Volumn 67, Issue 5, 2015, Pages 761-770

  Shi, Hui ^a   Wu, Yuchen ^a   Wang, Yang ^a   Zhou, Ming ^a   Yan, Shu ^a   Chen, Zhimin ^a   Gu, Dawei ^a   Cai, Yunqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLAVANONE DERIVATIVE; GELATINASE A; GELATINASE B; LIQUIRITIGENIN; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL; ANIMAL MODEL; C57BL MOUSE; CELL MOTION; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; PATHOLOGY; PREVENTION AND CONTROL; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; FLAVANONES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84934438416     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.1037962     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917, 2010.
2. Mazzocca A and Carloni V: The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 16, 1704-1717, 2009.
3. Russak JE and Rigel DS: Risk factors for the development of primary cutaneous melanoma. Dermatol Clin 30, 363-368, 2012.
4. Lucas R: Global Burden of Disease of Solar Ultraviolet Radiation, Environmental Burden of Disease Series, No. 13 [News release]. Geneva, Switzerland: World Health Organization, 2006.
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27, 6199-6206, 2009.
6. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12, 895-904, 2006.
7. McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6, 149-156, 2000.
8. Yang JM Xu Z, Wu H, Zhu H, Wu X, et al.: Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1, 420-427 2003.
9. Cheng CY, Hsieh HL, Hsiao LD, and Yang CM: PI3-K/Akt/JNK/NF-kappaB is essential for MMP-9 expression and outgrowth in human limbal epithelial cells on intact amniotic membrane. Stem Cell Res 9, 9-23, 2012.
10. Shih YW, Chen PS, Wu CH, Jeng YF, and Wang CJ: Alpha-chaconinereduced metastasis involves a PI3 K/Akt signaling pathway with downregulation of NF-kappaB in human lung adenocarcinoma A549 cells. J Agric Food Chem 55, 11035-11043, 2007.
11. Lee YC, Cheng TH, Lee JS, Chen JH, Liao YC, et al.: Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3 K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. Mol Cell Biochem 347, 103-115, 2011.
12. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96, 4240-4245, 1999.
13. Su Y, Gao L, Teng L, Wang Y, Cui J, et al.: Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3 K/Akt and NFkappaB/MMP-2 signaling pathways. J Transl Med 11, 132, 2013.
14. Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med 100, 704-713, 1984.
15. Gueven K, Kittler. H, Wolff. K, and Pehamberger H: Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant. Melanoma Research 11, 411-415, 2001.
16. Romagnolo DF and Selmin OI: Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 31, 206-238, 2012.
17. Sen T, Moulik S, Dutta A, Choudhury PR, Banerji A, et al.: Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci 84, 194-204, 2009.
18. Gu Y, Zhu CF, Iwamoto H, and Chen JS: Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J Gastroenterol 11, 6512-6517, 2005
19. Falcao MJ, Pouliquem YB, Lima MA, Gramosa NV, Costa-Lotufo LV, et al.: Cytotoxic flavonoids from Platymiscium floribundum. J Nat Prod 68, 423-426, 2005.
20. Xie SR, Wang Y, Liu CW, Luo K, and Cai YQ: Liquiritigenin inhibits serum-induced HIF-1alpha and VEGF expression via the AKT/mTORp70S6 K signalling pathway in HeLa cells. Phytother Res 26, 1133-1141, 2012.
21. Wang Y, Xie S, Liu C, Wu Y, Liu Y, et al.: Inhibitory effect of liquiritigenin on migration via downregulation proMMP-2 and PI3 K/Akt signaling pathway in human lung adenocarcinoma A549 cells. Nutr Cancer 64, 627-634, 2012.
22. Roy R, Yang J, and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27, 5287-5297, 2009.
23. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, et al.: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract 2847]. Proc Am Soc Clin Oncol 22, 708, 2003.
24. Dua P, Ingle A, and Gude RP: Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma. Int J Cancer 121, 1600-1608, 2007.
25. Lee TK, Poon RT, Wo JY, Ma S, Guan XY, et al.: Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res 67, 8800-8809, 2007.
26. Liu X, Chan SY, and Ho PC: Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemother Pharmacol 63, 167-174, 2008.
27. Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36, 1621-1630, 2000.
28. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10, 415-433, 2000.
29. Zhang XM, Huang SP, and Xu Q: Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway. Cancer Chemother Pharmacol 53, 82-88, 2004.
30. Lu Z, Lu N, Li C, Li F, Zhao K, et al.: Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 209, 211-220, 2012.
31. Ramer R, Eichele K, and Hinz B: Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells. Oncogene 26, 5822-5827, 2007.
32. Hijova E: Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 106, 127-132, 2005.
33. Stettner R, Bogusiewicz M, and Rechberger T: [Matrix metalloproteinases and their inhibitors in ovarian cancer progression-diagnostic and therapeutic implications]. Ginekol Pol 80, 47-53, 2009.
34. Engelman JA: Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9, 550-562, 2009.
35. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, and Bilanges B: The emerging mechanisms of isoform-specific PI3 K signalling. Nat Rev Mol Cell Biol 11, 329-341, 2010.
36. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, et al.: RAS/RAF/MEK/ERK and PI3 K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatol Res Pract 2012, 354191, 2012.
37. Stahl JM, Cheung M, and Sharma A: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 63, 2881-2890, 2003
38. Robertson GP: Functional and therapeutic significance of Akt deregulation in malignant. Cancer and Metastasis 24, 273-285, 2005
39. Shin DY, Lu JN, Kim GY, Jung JM, Kang HS, et al.: Anti-invasive activities of anthocyanins through modulation of tight junctions and suppression of matrix metalloproteinase activities in HCT-116 human colon carcinoma cells. Oncol Rep 25, 567-572, 2011.
40. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, et al.: Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 67, 535-544, 2010.